The goal of the Phase I portion of this clinical research study is to find the highest
tolerated dose of the combination of lenalidomide, all-trans retinoic acid (ATRA), and
dexamethasone that can be given to patients with relapsed or refractory multiple myeloma
(MM).
The goal of the Phase II portion of this study is to learn if ATRA when given in combination
with lenalidomide alone or with lenalidomide and dexamethasone can help to control multiple
myeloma.
In September 2015, the study was terminated due to slow accrual while still a Phase I study,
no additional registration or research performed under the Phase II portion of the study.